Status:
COMPLETED
Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration
Lead Sponsor:
AstraZeneca
Conditions:
Brain Distribution of [11C]AZ12807110 and AZD5213
Eligibility:
FEMALE
20-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate features of radioligand \[11C\]AZ12807110 and how much AZD5213 displaces radioligand from histamine receptors when given together.
Eligibility Criteria
Inclusion
- Healthy male and/or female volunteers between 20 to 45 years with suitable veins for cannulation or repeated venipuncture (pilot panel)
- Female must be of non-child bearing potential (pilot panel)
- BMI between 18 to 30 30 kg/m2
- Normal MRI scan
- Provision of signed, written and dated informed consent
Exclusion
- History of any clinically significant disease or disorder
- History or presence of gastrointestinal, hepatic or renal disease
- Prolonged QTcF \>450 ms or shortened QTcF \<340 ms or family history of long QT syndrome
- History of severe allergy or hypersensitivity or ongoing allergy or hypersensitivity
- Healthy volunteer suffers from claustrophobia
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT01194986
Start Date
November 1 2010
End Date
June 1 2011
Last Update
January 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Uppsala, Sweden